Bifurcation Warranted In Lotrel Patent Spat: Judge

Law360, New York (October 30, 2008, 12:00 AM EDT) -- A federal judge has agreed to bifurcate the trial in a patent infringement suit brought by Novartis AG to protect its hypertension drug Lotrel, writing that “the separation of issues would minimize jury confusion and promote judicial economy.”

The suit, which claims that Teva Pharmaceuticals USA Inc.'s abbreviated new drug application for the hypertension drug violated Novartis' patent for a combination of the active ingredients in Lotrel, has been pending in the U.S. District Court for the District of New Jersey for more than four years....
To view the full article, register now.